GPR55

Cerevance Announces Presentations at Two Medicinal Chemistry Conferences

Retrieved on: 
Tuesday, March 21, 2023
Central nervous system, Therapy, Eurosport 1, Drug discovery, Cerev Del, Mechanical philosophy, Therapeutic Targets Database, CNS, Calcium, GPR55, Microglia, SCI, Conference, Kinetics, Pharmaceutical industry

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present at two upcoming medicinal chemistry conferences.

Key Points: 
  • BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present at two upcoming medicinal chemistry conferences.
  • 7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets held March 27-28 in Cambridge, UK
    Binding Kinetics and Mechanistic PK/PD Modeling in Early Drug Discovery Conference held March 27-28 in Cambridge, UK
    Title: Identification of THIK-1 as a therapeutic target for neuroinflammatory diseases: Discovery and characterisation of a selective THIK-1 blocker
    Overview: The NETSseq platform can identify unexplored and druggable microglia targets, exemplified by THIK-1, as potential therapies for neurodegenerative diseases.
  • The discovery of a THIK-1 inhibitor, C101248, and its pharmacological profile, as well as its effect in microglia, is explored.
  • Overview: Three proprietary small molecule activators of GPR55 display unique signalling profiles when measuring the initial velocity of calcium and β-arrestin pathway activation.

Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Participates in Research Finding Promising Therapeutic Benefits of CBD in Parkinson's Disease Treatment

Retrieved on: 
Wednesday, October 12, 2022
SAN, CA, Cannabis, Drug Quality and Security Act, Disease, GPR55, Meritorious Autonomous University of Puebla, Medical cannabis, Neuropharmacology, Criticism of the Food and Drug Administration, Neuroscience, Parkinson's disease, The O.C., Autonomous university, Central nervous system, Securities Act of 1933, Neurochemistry, Autonomous University of Barcelona, Food, Mouse, Health, CEO, Safe harbor, Nature, Securities Exchange Act of 1934, Safety, OTC, GLOBE, DRUG, Frontiers Media, FDA, CNBC, Medical Marijuana, Inc., Drug, Medical device, CBD, Pharmacology

"In our model, we studied the effect of CBD administered to mice that were in a parkinsonian state.

Key Points: 
  • "In our model, we studied the effect of CBD administered to mice that were in a parkinsonian state.
  • To ensure the most scientifically reliable, valid, and trustworthy results, HempMeds provided its flagship RSHO-X 5,000 to aid in the studys execution.
  • "Our commitment is to provide free access to non-psychoactive cannabis and its benefits, said Raul Elizalde, CEO of HempMeds.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

Retrieved on: 
Tuesday, October 12, 2021
Emerald, Company, Pain, Lists of diseases, D, Severe cognitive impairment, University of Eastern Piedmont, CB1, University of Cordoba, University, SAN, Drug discovery, R, CB2, GLOBE, IP, Human, Investment, Terminology, Inflammation, U.S. Securities and Exchange Commission, GPR55, Ophthalmology, Cannabinoid, Environment, Security (finance), CA, Glaucoma, Therapy, CPIP, Leadership, OTCQB, Disease, Research, Risk, ECS, Pharmaceutical industry

The research initiative, referred to as the Cannabinoid Pharmaceutical Innovation Program (CPIP), will focus on targeting important signaling pathways in the endocannabinoid system to realize therapeutically beneficial effects.

Key Points: 
  • The research initiative, referred to as the Cannabinoid Pharmaceutical Innovation Program (CPIP), will focus on targeting important signaling pathways in the endocannabinoid system to realize therapeutically beneficial effects.
  • Led by cannabinoid research experts and scientific advisors to Skye, Drs.
  • Skye Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs.
  • Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

Cannabics Pharmaceuticals to Participate in the International Cannabis Research Society Annual Forum in Leiden, the Netherlands

Retrieved on: 
Tuesday, June 26, 2018
Cannabinoids, Cannabis, Neuroscience, International Cannabinoid Research Society, Health, GPR55, Endocannabinoid system, ICRS, Abnormal cannabidiol

The International Cannabinoid Research Society, ICRS, a non-political organization, is dedicated to scientific research in all fields of cannabinoids, ranging from biochemical, chemical and physiological studies of the endogenous cannabinoid system.

Key Points: 
  • The International Cannabinoid Research Society, ICRS, a non-political organization, is dedicated to scientific research in all fields of cannabinoids, ranging from biochemical, chemical and physiological studies of the endogenous cannabinoid system.
  • In attendance will be Dr Haleli Sharir, Dr Nir Kfir, and Dr. Eyal Ballan, the company's Co-Founder and CTO.
  • As a member of a research group, it was observed that human GPR55 can be activated by several types of cannabinoids.
  • Cannabics Pharmaceuticals Inc. (CNBX) is aUnited States-based public company that is developing cannabinoid diagnostic tests for the personalized treatment of cancer.